Management of Atrial Fibrillation with Rapid Ventricular Response

Immediate Transition to Oral Rate Control

The American College of Cardiology recommends initiating oral diltiazem or a beta-blocker for sustained rate control, with oral diltiazem 120-360 mg daily (extended release) being a logical continuation given successful IV diltiazem response, with typical starting doses of 120-180 mg daily 1
Alternatively, oral metoprolol tartrate 25-200 mg twice daily or metoprolol succinate 50-400 mg daily can be used, particularly if there are concerns about calcium channel blocker use 1

The American College of Cardiology recommends calculating the CHA₂DS₂-VASc score immediately to determine anticoagulation needs, and if CHA₂DS₂-VASc ≥2 in males or ≥3 in females, initiate oral anticoagulation with a direct oral anticoagulant (DOAC) or warfarin 1
DOACs are preferred over warfarin for most patients with non-valvular AFib, with options including apixaban 5 mg twice daily, rivaroxaban 20 mg once daily, edoxaban 60 mg once daily, or dabigatran 150 mg twice daily 1

The American College of Cardiology recommends screening for additional reversible causes of AFib, including assessing for obstructive sleep apnea, reviewing alcohol intake, and evaluating for acute illness, infection, or pulmonary embolism if clinically indicated 1

The American College of Cardiology recommends determining whether a patient would benefit from a rhythm control approach versus rate control alone, with rhythm control being particularly important if there is evidence of tachycardia-induced cardiomyopathy 1
Younger patients, those with recent-onset AFib, or highly symptomatic patients may benefit more from rhythm control, and if pursuing rhythm control, options include electrical cardioversion or pharmacological cardioversion with Class IC or Class III antiarrhythmics such as dofetilide 1

The American College of Cardiology recommends arranging close outpatient follow-up within 1-2 weeks to assess response to therapy, and if anticoagulation is initiated, ensure appropriate follow-up for monitoring (INR if warfarin, renal function if DOAC) 1

The American College of Cardiology recommends AV node ablation with permanent pacemaker implantation for AFib with RVR that has failed AV nodal blockers, amiodarone, and cardioversion 2
The American Heart Association suggests confirming adequate anticoagulation status, with the patient having been anticoagulated for at least 3 weeks prior to cardioversion attempts, or TEE should have excluded left atrial thrombus 3
The American College of Cardiology indicates that ruling out tachycardia-induced cardiomyopathy is crucial, as its presence strengthens the indication for definitive rate control via ablation 2

The American College of Cardiology recommends pharmacological cardioversion with Class IC or Class III antiarrhythmics, such as dofetilide, as a reasonable option before proceeding to ablation 3
The American College of Cardiology suggests considering combination therapy with digoxin plus a beta-blocker or amiodarone for rate control, particularly in heart failure with reduced ejection fraction 2
The American College of Cardiology indicates that AV node ablation with ventricular pacing is reasonable when pharmacological therapy remains insufficient or not tolerated, especially in cases of suspected or confirmed tachycardia-induced cardiomyopathy 2

The American Heart Association recommends a rhythm-control strategy with antiarrhythmic therapy for tachycardia-induced cardiomyopathy, as it becomes more important than simple rate control 3

The American College of Cardiology advises against using IV calcium channel blockers or beta-blockers if decompensated heart failure is present, as it may cause harm 2
The American Heart Association warns against initiating dofetilide as an outpatient, due to potential risks 3